Testing adjunct cromoglicate for schizophrenia symptoms
Part of Mental health clinical trials.
This trial studies whether adding cromoglicate to your usual antipsychotic medicine can improve schizophrenia symptoms. It’s designed for outpatients who are already on a stable treatment and still have certain ongoing symptom scores.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign a written consent form to join the study
- You’re between 18 and 60 years old
- You have a diagnosis of schizophrenia or schizoaffective disorder
- You’ve been on the same antipsychotic (APD) at a stable dose for at least 1 month and will keep it steady during the study
- Your symptom ratings fit the trial’s specific schizophrenia score targets (PANSS total 60, and at least one “positive” symptom item score 4+)
- Your psychosis has been going on for less than 7 years (this is preferred)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests whether acetazolamide can help people with treatment-resistant schizophrenia. It aims to see if adding this medication improves symptoms when standard antipsychotics haven’t worked enough.
This study tests a new treatment that may help with thinking and memory problems in people with schizophrenia. It is for people whose schizophrenia symptoms are stable and who are already on a steady medication.
This trial tests a new drug, GXV813, to see if it helps reduce symptoms in people with schizophrenia who are currently hospitalized due to a sudden worsening of their condition. It compares the drug's safety and effect against a placebo over several weeks.
This trial tests a combination of an NMDA-targeting medicine and an anti-inflammatory treatment for people with schizophrenia that has not responded well to several standard treatments, including clozapine. If you qualify, the goal is to see whether this combination improves symptoms more than usual care.
This trial tests an experimental oral drug (emraclidine) to see if it helps symptoms of schizophrenia and how it moves through the body. It looks at two groups of participants: those with stable symptoms and those having an acute flare-up.
This study tests whether a combination of an antihistamine called clemastine plus aerobic exercise can help improve thinking and memory problems in people with schizophrenia. It aims to see if this approach can repair nerve insulation in the brain, potentially restoring cognitive function.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.